NTRA — Natera, Inc.

Natera (NTRA) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $666 million for Q4 2025, representing a 40% year-over-year growth and exceeding pre-announced expectations by $6 million.
• Tests Processed: Approximately 924,000 tests, with 225,000 MRD (Minimal Residual Disease) tests processed in Q4, a 56% increase from Q4 2024.
• Gross Margin: 66.9% for Q4, with an organic gross margin of 63.7% after excluding revenue true-ups.
• Cash Flow: Generated over $107 million in cash flow for the full year 2025.
• Operating Losses: Significantly narrowed in Q4, with a net income reported due to a one-time deferred tax item related to the Foresight acquisition.
• Balance Sheet: Maintained a strong position with over $1 billion in cash and securities.

2. Strategic Updates and Business Highlights

• Product Launches: Launched the 21-gene Fetal Focus single-gene NIPT test and expanded the MRD product portfolio with genome versions of Signatera and Latitude tests.
• Clinical Advancements: Published significant data supporting the efficacy of the Latitude Tissue-Free MRD test and the Fetal Focus test, with the latter receiving an oral plenary presentation at a major conference.
• Market Adoption: Over 50% of oncologists in the U.S. ordered a Signatera test in Q4, indicating strong adoption of MRD testing.
• Acquisition: Completed the acquisition of Foresight Diagnostics, enhancing capabilities in phased variant technology for MRD testing.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $2.62 billion and $2.7 billion, with gross margins projected between 63% and 65%.
• Operational Focus: Plans to hold SG&A stable while increasing R&D investments, anticipating another strong cash flow year.
• Volume Growth: Continued growth expected in women's health and organ health products, with a focus on expanding reimbursement coverage for Signatera.

4. Bad News, Challenges, or Points of Concern

• Reimbursement Risks: Some tests are still awaiting broader Medicare coverage, which could impact ASPs (Average Selling Prices) and revenue.
• Market Competition: The competitive landscape in MRD testing is intensifying, particularly with new entrants and evolving technologies.
• Operational Caution: While the company is optimistic about growth, there are concerns regarding the sustainability of Q4's gross margin improvements and the potential for variability in future quarters.

5. Notable Q&A Insights

• Signatera ASP Dynamics: Changes in Medicare reimbursement rates are expected to net out, but there is potential upside from broader coverage decisions.
• Market Share in Women's Health: Natera is experiencing growth in women's health, particularly with the new Fetal Focus test, although specific competitor data is not available.
• Hematology Opportunities: Limited current contribution from lymphoma and multiple myeloma, but viewed as a significant future growth opportunity.
• International Expansion: Anticipated approval for Signatera in Japan in 2026, with potential for strong revenue impact in 2027.

Overall, Natera reported a strong performance in Q4 2025, with significant growth in revenue and test volumes, while also outlining ambitious plans for 2026 amidst some operational and competitive challenges.